CLINICAL TRIALS PROFILE FOR RAXIBACUMAB
✉ Email this page to a colleague
All Clinical Trials for raxibacumab
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00639678 ↗ | A Study to Evaluate the Safety and Tolerability of Raxibacumab in Healthy Subjects | Completed | Emergent BioSolutions | Phase 3 | 2008-03-01 | To evaluate the safety and tolerability of raxibacumab in healthy subjects. |
| NCT00639678 ↗ | A Study to Evaluate the Safety and Tolerability of Raxibacumab in Healthy Subjects | Completed | GlaxoSmithKline | Phase 3 | 2008-03-01 | To evaluate the safety and tolerability of raxibacumab in healthy subjects. |
| NCT00639678 ↗ | A Study to Evaluate the Safety and Tolerability of Raxibacumab in Healthy Subjects | Completed | Human Genome Sciences Inc. | Phase 3 | 2008-03-01 | To evaluate the safety and tolerability of raxibacumab in healthy subjects. |
| NCT00639678 ↗ | A Study to Evaluate the Safety and Tolerability of Raxibacumab in Healthy Subjects | Completed | Human Genome Sciences Inc., a GSK Company | Phase 3 | 2008-03-01 | To evaluate the safety and tolerability of raxibacumab in healthy subjects. |
| NCT02339155 ↗ | Effect of Raxibacumab on Immunogenicity of Anthrax Vaccine Adsorbed | Completed | GlaxoSmithKline | Phase 4 | 2015-02-24 | This study, as a post-marketing commitment to the Food and Drug Administration, is designed to detect the effect of raxibacumab on anthrax vaccine adsorbed (AVA) immunogenicity in a healthy volunteer population. This is a randomized, open-label, parallel group, two arm study to compare the immunogenicity of AVA at 4 weeks after the first AVA dose, when AVA is administered alone or concomitantly with raxibacumab. The study is planned to enroll approximately 30 to 534 subjects in up to 3 cohorts. The total duration of the study will be approximately 26 weeks. The dates reflect cohort 1. |
| NCT02339155 ↗ | Effect of Raxibacumab on Immunogenicity of Anthrax Vaccine Adsorbed | Completed | Emergent BioSolutions | Phase 4 | 2015-02-24 | This study, as a post-marketing commitment to the Food and Drug Administration, is designed to detect the effect of raxibacumab on anthrax vaccine adsorbed (AVA) immunogenicity in a healthy volunteer population. This is a randomized, open-label, parallel group, two arm study to compare the immunogenicity of AVA at 4 weeks after the first AVA dose, when AVA is administered alone or concomitantly with raxibacumab. The study is planned to enroll approximately 30 to 534 subjects in up to 3 cohorts. The total duration of the study will be approximately 26 weeks. The dates reflect cohort 1. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for raxibacumab
Condition Name
Clinical Trial Locations for raxibacumab
Trials by Country
Clinical Trial Progress for raxibacumab
Clinical Trial Phase
Clinical Trial Sponsors for raxibacumab
Sponsor Name
